Alexander Sverstad, MD reveals in lecture that Eye Movement Perimetry is capable of distinghuishing healthy individuals from those with mild to moderate glaucoma as effectively as SAP

Alexander Sverstad is a senior ophthalmologist and PhD candidate in the research group led by Professor Goran Petrovski at the Center for Eye Research and Innovative Diagnostics. He is currently conducting a study at Oslo University Hospital (Ullevål) and at Vestfold Hospital, focusing on the eye’s reaction abilities in patients with glaucoma using BulbiCAM. (link to his introduction in Norwegian: Glaukom – en snikende trussel mot synet – Norges Blindeforbund)

Alexander held a lecture at the EGRET AAA meeting on March 12th in Trondheim on “Physiology and Pathophysiology of Visual Functions in Glaucoma: New Markers Using BulbiCAM.” Link to the EGRET AAA article: Seeing the light! Our 4th EGRET-AAA workshop in Trondheim | EGRET AAA

His presentation focused on advancements in glaucoma diagnostics, emphasizing how BulbiCAM’s Eye Movement Perimetry (EMP) + Pupil test provides new insights into visual function assessment and has the potential of providing enormous clinical value, particularly in detecting and monitoring mild to moderate glaucoma.

Alexander highlighted how BulbiCAM’s ability to track eye movements, measure saccadic reaction time (SRT), and analyse pupil responses offers a more objective and efficient method for identifying glaucoma-related dysfunction.
One of the key points in his lecture was the correlation between increased SRTs and glaucoma related damage,
and that our EMP is capable of distinguishing healthy individuals from those with mild to moderate glaucoma as effectively as standard automated perimetry (SAP).

Additionally, BulbiCAM’s automated pupil function analysis provides precise measurements of both dynamic and static pupillary light responses. While detecting relative afferent pupillary defects (RAPD) is crucial for identifying asymmetric optic nerve damage, precise pupil diameter measurements may help detect glaucoma even in its early stages. This non-invasive approach adds valuable diagnostic potential for early glaucoma detection and disease progression tracking, further strengthening the role of BulbiCAM in clinical practice.

Alexander concluded his lecture with a call for further research and clinical validation of eye-tracking technologies in ophthalmology, especially in subjects with pre-perimetric glaucoma and glaucoma suspects. The presentation received positive feedback from attendees, underscoring the growing interest in integrating innovative diagnostic approaches into clinical practice.

Finally, we are pleased to announce that Alexander Sverstad’s first abstract on his glaucoma study with BulbiCAM, supervised by Prof. Goran Petrovski, has been accepted for presentation at ARVO 2025 in Salt Lake City.